| |
| Physical Characters and Index |
MF:C190H355N101O37
MW:4646.49 |
| |
| Use and description |
| ES2 can act as senolytics for eliminating senescent human cancer cells both in cell culture and in orthotopic mouse models. It disrupts FOXO4-TP53 foci, activates TP53 mediated apoptosis and preferentially binds FOXO4 compared to TP53. Intratumoural delivery of ES2 plus a BRAF inhibitor results in a significant increase in apoptosis and a survival advantage in mouse models of melanoma. Repeated systemic delivery of ES2 to older mice results in reduced senescent cell numbers in the liver with minimal toxicity. When compared with FOXO4-DRI peptide and found that, while FOXO4-DRI has minimal lytic activity in dividing cells, ES2 peptide had 3-7 times higher senolytic activity |
|
